Susan E. Hoover
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Susan E. Hoover has a total of 211 co-authors. Here are the top co-authors by number of shared publications:
- Neil M. Ampel
College of Medicine University of Arizona , Tucson, Arizona
2 shared publications Adam M. Ruff
Affiliation Division of Pulmonary and Critical Care, University of Kansas Medical Center, Kansas City, Kansas City, United States of America
1 shared publicationAdeyinka O. Laiyemo
Affiliation Department of Medicine, Howard University, Washington, DC, United States of America
1 shared publicationAlan T. N. Tita
Affiliation Department of Obstetrics and Gynecology and Center for Women’s Reproductive Health, University of Alabama at Birmingham, Birmingham, Alabama, United States of America
1 shared publicationAlexander W. Charney
Affiliation Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America
1 shared publication- Alfredo E. Urdaneta
Department of Emergency Medicine, Stanford Medicine, Palo Alto, CA
1 shared publication
Latest Publications
- Open Access
- 23 June 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (6) , e0286297
Researching COVID to Enhance Recovery (RECOVER) adult study protocol: Rationale, objectives, and design
Importance: SARS-CoV-2 infection can result in ongoing, relapsing, or new symptoms or other health effects after the acute phase of infection; termed post-acute sequelae of SARS-CoV-2 infection (PASC), or long COVID. The characteristics, prevalence, trajectory and mechanisms of PASC are ill-defined. The objectives of the Researching COVID to Enhance Recovery (RECOVER) Multi-site Observational Study of PASC in Adults (RECOVER-Adult) are to: (1) characterize PASC prevalence; (2) characterize the symptoms, organ dysfunction, natural history, and distinct phenotypes of PASC; (3) identify demographic, social and clinical risk factors for PASC onset and recovery; and (4) define the biological mechanisms underlying PASC pathogenesis.Methods: RECOVER-Adult is a combined prospective/retrospective cohort currently planned to enroll 14,880 adults aged ≥18 years. Eligible participants either must meet WHO criteria for suspected, probable, or confirmed infection; or must have evidence of no prior infection. Recruitment occurs at 86 sites in 33 U.S. states, Washington, DC and Puerto Rico, via facility- and community-based outreach. Participants complete quarterly questionnaires about symptoms, social determinants, vaccination status, and interim SARS-CoV-2 infections. In addition, participants contribute biospecimens and undergo physical and laboratory examinations at approximately 0, 90 and 180 days from infection or negative test date, and yearly thereafter. Some participants undergo additional testing based on specific criteria or random sampling. Patient representatives provide input on all study processes. The primary study outcome is onset of PASC, measured by signs and symptoms. A paradigm for identifying PASC cases will be defined and updated using supervised and unsupervised learning approaches with cross-validation. Logistic regression and proportional hazards regression will be conducted to investigate associations between risk factors, onset, and resolution of PASC symptoms.Discussion: RECOVER-Adult is the first national, prospective, longitudinal cohort of PASC among US adults. Results of this study are intended to inform public health, spur clinical trials, and expand treatment options.Registration: NCT05172024.
- 23 June 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (6) , e0286297
Open AccessResearching COVID to Enhance Recovery (RECOVER) adult study protocol: Rationale, objectives, and design
Importance: SARS-CoV-2 infection can result in ongoing, relapsing, or new symptoms or other health effects after the acute phase of infection; termed post-acute sequelae of SARS-CoV-2 infection (PASC), or long COVID. The characteristics, prevalence, trajectory and mechanisms of PASC are ill-defined. The objectives of the Researching COVID to Enhance Recovery (RECOVER) Multi-site Observational Study of PASC in Adults (RECOVER-Adult) are to: (1) characterize PASC prevalence; (2) characterize the symptoms, organ dysfunction, natural history, and distinct phenotypes of PASC; (3) identify demographic, social and clinical risk factors for PASC onset and recovery; and (4) define the biological mechanisms underlying PASC pathogenesis.Methods: RECOVER-Adult is a combined prospective/retrospective cohort currently planned to enroll 14,880 adults aged ≥18 years. Eligible participants either must meet WHO criteria for suspected, probable, or confirmed infection; or must have evidence of no prior infection. Recruitment occurs at 86 sites in 33 U.S. states, Washington, DC and Puerto Rico, via facility- and community-based outreach. Participants complete quarterly questionnaires about symptoms, social determinants, vaccination status, and interim SARS-CoV-2 infections. In addition, participants contribute biospecimens and undergo physical and laboratory examinations at approximately 0, 90 and 180 days from infection or negative test date, and yearly thereafter. Some participants undergo additional testing based on specific criteria or random sampling. Patient representatives provide input on all study processes. The primary study outcome is onset of PASC, measured by signs and symptoms. A paradigm for identifying PASC cases will be defined and updated using supervised and unsupervised learning approaches with cross-validation. Logistic regression and proportional hazards regression will be conducted to investigate associations between risk factors, onset, and resolution of PASC symptoms.Discussion: RECOVER-Adult is the first national, prospective, longitudinal cohort of PASC among US adults. Results of this study are intended to inform public health, spur clinical trials, and expand treatment options.Registration: NCT05172024.
- Open Access
- 7 February 2022
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 2 (1) , e21
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody prevalence in a healthcare worker population exceeded self-reported infection rates, 2020
A study of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence at a healthcare institution prior to the availability of vaccine showed that seroprevalence in the cohort increased over 6 months from 25% to 55%. The number of employees with antibodies was higher than the number who reported an exposure or diagnosis at each time point.
- 7 February 2022
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 2 (1) , e21
Open AccessSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody prevalence in a healthcare worker population exceeded self-reported infection rates, 2020
A study of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence at a healthcare institution prior to the availability of vaccine showed that seroprevalence in the cohort increased over 6 months from 25% to 55%. The number of employees with antibodies was higher than the number who reported an exposure or diagnosis at each time point.
- 7 May 2019
- Published by Springer Nature in Rheumatology International
- Vol. 39 (7) , 1257-1262
Management of asymptomatic coccidioidomycosis in patients with rheumatic diseases
Coccidioidomycosis is an endemic fungal infection common in the southwestern United States. Some rheumatology clinics periodically screen patients with coccidioidal serology, resulting in the identification of patients who are serologically positive but without clinical symptoms. The management of such patients is unclear. A retrospective study was conducted between 2007 and 2015 at two arthritis centers in Tucson, Arizona. The asymptomatic patients were identified who were receiving disease-modifying antirheumatic agents and had a positive coccidioidal serology. Serological testing including IgM and IgG was performed by enzyme immunoassay (EIA), immunodiffusion (IDTP and IDCF), or complement fixation. Out of 71 patients who were identified with positive coccidioidal serologies, 19 were asymptomatic. 18/19 patients continued antirheumatic therapy, 13 without interruption. 13/19 patients received no antifungal treatment, including 10 who remained on antirheumatic treatment. The other six were started on fluconazole, ranging from 8 to 73 months (median 30.5 months). After a median follow-up of 43 months, no patient developed clinically active coccidioidomycosis. Overall, 14 had only a positive EIA serological test. These results suggest that continued antirheumatic therapy is safe in asymptomatic patients with positive coccidioidal serological tests and that routine implementation of antifungal treatment may not always be warranted. The findings also raise concern regarding the utility of routine serological testing of asymptomatic patients residing in the coccidioidal endemic area, mainly using the EIA test.
- 7 May 2019
- Published by Springer Nature in Rheumatology International
- Vol. 39 (7) , 1257-1262
Management of asymptomatic coccidioidomycosis in patients with rheumatic diseases
Coccidioidomycosis is an endemic fungal infection common in the southwestern United States. Some rheumatology clinics periodically screen patients with coccidioidal serology, resulting in the identification of patients who are serologically positive but without clinical symptoms. The management of such patients is unclear. A retrospective study was conducted between 2007 and 2015 at two arthritis centers in Tucson, Arizona. The asymptomatic patients were identified who were receiving disease-modifying antirheumatic agents and had a positive coccidioidal serology. Serological testing including IgM and IgG was performed by enzyme immunoassay (EIA), immunodiffusion (IDTP and IDCF), or complement fixation. Out of 71 patients who were identified with positive coccidioidal serologies, 19 were asymptomatic. 18/19 patients continued antirheumatic therapy, 13 without interruption. 13/19 patients received no antifungal treatment, including 10 who remained on antirheumatic treatment. The other six were started on fluconazole, ranging from 8 to 73 months (median 30.5 months). After a median follow-up of 43 months, no patient developed clinically active coccidioidomycosis. Overall, 14 had only a positive EIA serological test. These results suggest that continued antirheumatic therapy is safe in asymptomatic patients with positive coccidioidal serological tests and that routine implementation of antifungal treatment may not always be warranted. The findings also raise concern regarding the utility of routine serological testing of asymptomatic patients residing in the coccidioidal endemic area, mainly using the EIA test.
- 24 September 2015
- Published by Springer Nature in Current Fungal Infection Reports
- Vol. 9 (4) , 253-258
Pathogenesis of Coccidioidomycosis
- 24 September 2015
- Published by Springer Nature in Current Fungal Infection Reports
- Vol. 9 (4) , 253-258
Pathogenesis of Coccidioidomycosis
- 1 September 2014
- Published by Wolters Kluwer Health in Infectious Diseases in Clinical Practice
- Vol. 22 (5) , 279-282
Nocardiosis at a University Medical Center in the American Southwest
Background Nocardia species cause serious infections in both immunocompromised and normal hosts. When nocardiosis is diagnosed or suspected, empirical therapy is often necessary while awaiting identification and susceptibility testing. In addition, species distribution varies regionally, so an understanding of locally prevalent species may help guide therapy. Methods A retrospective review of cases of nocardiosis in a tertiary-care teaching hospital and transplant center during the past 15 years, including host characteristics, antibiotic susceptibility, and initial treatment, was conducted. Results We identified 88 cases of nocardiosis during the past 15 years. Risk factors included organ or tissue transplantation in 36 patients and other immunosuppressive conditions or chronic lung disease in 31. Most patients (73) had pulmonary infection, 8 with simultaneous involvement at another site. N. cyriacigeorgica was the most commonly identified species, followed by N. farcinica. Species distribution was similar among transplant and nontransplant patients. Most isolates were susceptible to sulfamethoxazole/trimethoprim, imipenem, and/or ceftriaxone. Conclusions At a transplant center in the American Southwest, N. cyriacigeorgica was the predominant species isolated. Initial therapy with sulfamethoxazole/trimethoprim and a β-lactam is appropriate for most patients.
- 1 September 2014
- Published by Wolters Kluwer Health in Infectious Diseases in Clinical Practice
- Vol. 22 (5) , 279-282
Nocardiosis at a University Medical Center in the American Southwest
Background Nocardia species cause serious infections in both immunocompromised and normal hosts. When nocardiosis is diagnosed or suspected, empirical therapy is often necessary while awaiting identification and susceptibility testing. In addition, species distribution varies regionally, so an understanding of locally prevalent species may help guide therapy. Methods A retrospective review of cases of nocardiosis in a tertiary-care teaching hospital and transplant center during the past 15 years, including host characteristics, antibiotic susceptibility, and initial treatment, was conducted. Results We identified 88 cases of nocardiosis during the past 15 years. Risk factors included organ or tissue transplantation in 36 patients and other immunosuppressive conditions or chronic lung disease in 31. Most patients (73) had pulmonary infection, 8 with simultaneous involvement at another site. N. cyriacigeorgica was the most commonly identified species, followed by N. farcinica. Species distribution was similar among transplant and nontransplant patients. Most isolates were susceptible to sulfamethoxazole/trimethoprim, imipenem, and/or ceftriaxone. Conclusions At a transplant center in the American Southwest, N. cyriacigeorgica was the predominant species isolated. Initial therapy with sulfamethoxazole/trimethoprim and a β-lactam is appropriate for most patients.